WOCKPHARMA2023-10-012023-12-31 WOCKPHARMA2023-10-012023-12-31 WOCKPHARMA2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member WOCKPHARMA2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532300 WOCKPHARMA NA Wockhardt Limited Equity 2023-04-01 2024-03-31 2024-02-14 2024-02-05 INR Crores Third quarter 11:45:00 14:25:00 2024-02-14 2024-02-14 Not applicable Single segment Pharmaceuticals 2023-10-01 2023-12-31 Unaudited Standalone 2880000000.00 50000000.00 2930000000.00 800000000.00 450000000.00 -70000000.00 590000000.00 610000000.00 430000000.00 860000000.00 3670000000.00 -740000000.00 0.00 -740000000.00 0.00 0.00 0.00 0.00 -740000000.00 0.00 0.00 0.00 0.00 -740000000.00 10000000.00 -730000000.00 0.00 0.00 720000000.00 5 -5.14 -5.14 0.00 0.00 -5.14 -5.14 0.00 0.00 0.00 Notes To Standalone Results :- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 14, 2024. The results have been subjected to limited review by the Statutory Auditors of the Company. 2)(a) The Company had accounted for a contract asset of Rs. 50 crores pursuant to a contract manufacturing agreement. The Customer is yet to fulfil its contractual obligations and commitments. Though, the Company is pursuing various options and taking necessary actions related to this matter, given the uncertainty, Company had provided for this contract asset and had disclosed it as 'Exceptional items' during previous year. Company had also purchased certain specific inventory for this contract which has not been used. Company is continuing to evaluate alternate options to liquidate/ utilize such inventory, pending which, during the current period, the Company has made a provision of Rs 14 crores for such inventory basis the current assessment and information available as on date. This expenditure is also reported as an ‘Exceptional item’. (b) The Company had received advances for supply of goods from Wockhardt Bio AG, a majorly held foreign subsidiary of the Company, of which USD 89 million had been outstanding as at March 31, 2022. In accordance with the direction of Reserve Bank of India (RBI) / Authorised Dealer (AD) Bank, such advances were supposed to be adjusted only against supply of goods by the Company. Accordingly, this advance amount received was accounted at the historical transaction exchange rate in accordance with Ind AS 21- 'The Effects of Changes in Foreign Exchange Rates' The Company, as part of normal business, had also been providing services including but not limited to R&D services and assignment of rights over its new chemical entities (NCE) to the aforesaid foreign subsidiary and had outstanding receivables of USD 113 million. Since the Company had not been able to supply the goods, the Company received an approval from RBI/ AD on March 10, 2023, for adjustment of the aforesaid advance with these outstanding receivables. Pursuant to this, Company had recognised an exchange loss of Rs. 185 crore on the settlement of the advance and receivables of USD 89 million under 'Exceptional items' during the previous year. Given that these receivables and advance liability are eliminated on consolidation, this settlement did not have any impact on the consolidated financial results of the Group for the previous period. 3) During the quarter ended December 31, 2023 , the Company has allotted 6,900 ( Year to date: 13,150) Equity shares of face value of Rs. 5/- each pursuant to exercise of employee stock options. 4) The Company is exclusively into Pharmaceutical business Segment. 5) EPS for the quarter and nine months ended December 31, 2023 is not annualised. Single segment 2023-04-01 2023-12-31 Unaudited Standalone 7990000000.00 170000000.00 8160000000.00 1930000000.00 1210000000.00 120000000.00 1850000000.00 1780000000.00 1310000000.00 2780000000.00 10980000000.00 -2820000000.00 -140000000.00 -2960000000.00 0.00 0.00 0.00 0.00 -2960000000.00 0.00 0.00 0.00 0.00 -2960000000.00 20000000.00 -2940000000.00 0.00 0.00 720000000.00 5 -20.55 -20.55 0.00 0.00 -20.55 -20.55 0.00 0.00 0.00 Other Expenses 860000000.00 Other Expenses 2780000000.00 10000000.00 20000000.00 0.00 0.00 0.00 0.00